Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial.
Summary
In a multicenter, randomized, intra-patient controlled phase II trial (n=23), denovoSkin achieved significantly better scar quality at 3 months versus split-thickness skin grafts by observer-rated POSAS, in a cohort largely composed of post-burn scars. The approach aims to reduce donor-site morbidity while improving functional and cosmetic outcomes.
Key Findings
- Randomized intra-patient comparison (n=23) showed superior observer-rated scar quality for denovoSkin at 3 months versus STSG (POSAS 23.4 vs 27.9).
- Cohort characteristics: mean age 37.4 years, 65% male, 70% post-burn scars, enabling clinically relevant comparison.
- Bio-engineered autologous dermo-epidermal construct aims to minimize donor-site morbidity while maintaining graft function.
Clinical Implications
denovoSkin may reduce donor-site morbidity and improve scar outcomes in extensive full-thickness defects (e.g., burns, scars), supporting further phase III trials and payer adoption pathways.
Why It Matters
This RCT provides controlled human data that a bio-engineered autologous dermo-epidermal construct can surpass standard grafting in scar quality, addressing a long-standing limitation of reconstructive surgery.
Limitations
- Small sample size limits precision and subgroup analyses
- Partial reporting (interim 1-year results) and limited long-term durability data
Future Directions
Conduct adequately powered phase III RCTs with longer follow-up, cost-effectiveness, and patient-reported outcomes; assess indications beyond burns and optimize manufacturing logistics.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- II - Single randomized controlled trial with intra-patient control
- Study Design
- OTHER